deferiprone


( Last Updated : May 10, 2022)
Generic Name:
deferiprone
Project Status:
Pending
Therapeutic Area:
Transfusional iron overload
Manufacturer:
Chiesi Canada Corp.
Call for patient/clinician input open:
Brand Name:
Ferriprox
Project Line:
Reimbursement Review
Project Number:
SR0741-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with transfusional iron overload due to sickle cell disease (SCD) or other anemias.
Fee Schedule:
Pending
Indications:
For the treatment of patients with transfusional iron overload due to sickle cell disease (SCD) or other anemias.
Date NOC Issued:
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.